exce estim growth
life scienc tool diagnost forecast increas
ep ahead consensu ep beat
estim stronger revenu off-set weaker profit factor line
ad importantli releas initi guidanc call ep includ ge
biopharma accret midpoint vs consensu reflect higher-
than-expect organ growth lower ge biopharma financ cost better ge
biopharma core growth perform rais ep
growth tailwind aforement factor
revenu profit exceed plan organ revenu beat estim
strength life scienc vs estimate diagnost vs
dynam continu rose line view
gross margin expand bp bp plan oper expens declin
bp albeit bp view core oper margin expans bp net/net
ebitda margin expand bp bp plan
share may grind higher share rose vs
ytd view share move higher latest core growth upsid
particularli across life scienc diagnost segment guidanc
suggest sustain core growth momentum excl extra sell day also
encourag top-line guid point core growth continu
strength life scienc diagnost well long-term growth prospect
increas exposur faster-grow end-market particularli ge await
greater disclosur certain intern market name underli core growth china
china sale well greater detail fx tariff dynam
upcom year question call ge biopharma update/divestitur end-market
demand trend particularli biopharma/china upside/downsid guidanc risk
util macro condit miscu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
lead manufactur system instrument
consum broad array purpos custom primari
dental environment health/appli scienc
blue sky scenario assum signific acceler
key end market global signific rebound dental trend better
expect implement db acquir compani market
share gain materi margin expans
grey sky scenario base signific weak
key end market prolong weak dental demand trend
deceler core growth acquisit integr headwind
 close
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
